Possible changes in glucose metabolism induced by radioligand therapy in patients with neuroendocrine neoplasms
Radioligand therapy potentially increases fasting glucose concentrations, probably due to changes in peripheral glucose metabolism. However, it remains a safe treatment method for patients with neuroendocrine neoplasms and does not cause severe glycaemic adverse events related to glucose metabolism.
Authors
- Arkadiusz Lubas (ORCID: https://orcid.org/0000-0002-3248-4615)
- Barbara Bober (ORCID: https://orcid.org/0000-0002-1880-1389)
- Dorota Brodowska-Kania (ORCID: https://orcid.org/0000-0002-3328-1537)
- Marek Saracyn (ORCID: https://orcid.org/0000-0002-5800-0500)
- Adam Daniel Durma (ORCID: https://orcid.org/0000-0001-7103-2577)
- Grzegorz Kamiński (ORCID: https://orcid.org/0000-0002-2357-0634)
- Anna Drozd (ORCID: https://orcid.org/0000-0003-0251-7495)
- Katarzyna Janiak (ORCID: https://orcid.org/0000-0002-0484-7052)
- Gabriela Różańska-Grzelak
Institutions
- National Academy of Medicine (US)
Publication Details
- Journal
- Endokrynologia Polska
- Published
- 2024-12-30
- DOI
- https://doi.org/10.5603/ep.101234
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Wojskowy Instytut Medyczny